Recent News for BCEL - Atreca, Inc.

Date Title
Dec 5 CLVS, AUPH, ESTC and HOV among midday movers
Dec 4 Healthcare - Top 5 Gainers / Losers
Dec 3 Atreca up 25% on advancement of lead candidate
Dec 3 CBL, CARA, VRAY and BOLD among midday movers
Dec 3 UniQure and ViewRay among healthcare gainers; Cara Therapeutics among losers
Dec 3 Atreca Announces FDA Clearance of Investigational New Drug Application for ATRC-101
Nov 20 Atreca (BCEL) Investor Presentation - Sliideshow
Nov 14 Atreca to Present at Two Upcoming Investor Conferences
Nov 12 Atreca EPS beats by $0.15
Nov 12 Atreca Reports Third Quarter 2019 Financial Results and Recent Corporate Developments
Nov 5 Atreca to Highlight ATRC-101 Preclinical Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Oct 11 The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout
Sep 19 Do Institutions Own Shares In Atreca, Inc. (NASDAQ:BCEL)?
Sep 4 Citi likes Intercept Pharma in premarket analyst action
Aug 26 Atreca Announces Appointment of Dr. Lindsey Rolfe to its Board of Directors
Aug 21 The Daily Biotech Pulse: Ra Medical Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform
Aug 17 Stanford University Now Owns Stakes in Uber and Pinterest Stock
Aug 13 Atreca EPS misses by $2.71
Aug 13 Atreca Reports Second Quarter 2019 Financial Results and Recent Corporate Developments
Aug 12 90 Biggest Movers From Friday
Aug 9 CNDT and DXC among midday losers
Aug 6 The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering
Jul 26 Stocks That Managed to Breach 52-Week Lows Friday
Jul 15 Stifel: Atreca Offers Attractive Oncology Drug Development Play
Jul 15 Wells sees 33% upside in Gilead in premarket analyst action

Back to the Main BCEL Page...